INT21467

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1986
Last Reported 2006
Negated 1
Speculated 0
Reported most in Abstract
Documents 18
Total Number 18
Disease Relevance 2.84
Pain Relevance 11.91

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Cck) extracellular region (Cck)
Anatomy Link Frequency
nucleus accumbens 4
cerebral cortex 4
IPN 4
area postrema 2
Cck (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Cholecystokinin 146 100.00 Very High Very High Very High
IPN 11 100.00 Very High Very High Very High
Enkephalin 7 100.00 Very High Very High Very High
Dopamine 31 99.92 Very High Very High Very High
antagonist 50 99.88 Very High Very High Very High
agonist 50 99.60 Very High Very High Very High
opiate 36 99.44 Very High Very High Very High
gABA 13 99.40 Very High Very High Very High
Nucleus accumbens 2 99.40 Very High Very High Very High
cerebral cortex 10 99.16 Very High Very High Very High
Disease Link Frequency Relevance Heat
Attention Deficit Hyperactivity Disorder 8 97.62 Very High Very High Very High
Pain 55 96.48 Very High Very High Very High
Pressure And Volume Under Development 4 96.40 Very High Very High Very High
Opiate Addiction 4 96.12 Very High Very High Very High
Body Weight 8 90.20 High High
Anxiety Disorder 92 79.00 Quite High
Neuroblastoma 1 76.72 Quite High
Pancreatitis 33 75.00 Quite High
Pancreatic Cancer 12 72.08 Quite High
Disease 6 66.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In animals which showed almost total loss of GABAB receptors. 125I-Bolton Hunter CCK binding in the IPN was reduced from 1.83 +/- 0.28 pmol/g wet weight to 0.87 +/- 0.16 pmol/g wet weight.
Negative_regulation (loss) of CCK Binding (binding) of in IPN associated with ipn
1) Confidence 0.57 Published 1988 Journal Brain Res. Section Abstract Doc Link 3408996 Disease Relevance 0 Pain Relevance 0.41
Pancreatic function was decreased significantly with no alteration in CCK receptor binding.
Neg (no) Negative_regulation (decreased) of CCK Binding (binding) of associated with cholecystokinin
2) Confidence 0.48 Published 2003 Journal Tob Induc Dis Section Abstract Doc Link PMC2671550 Disease Relevance 0.78 Pain Relevance 0.39
Pancreatic function was decreased significantly with no alteration in CCK receptor binding.
Negative_regulation (decreased) of CCK Binding (binding) of associated with cholecystokinin
3) Confidence 0.48 Published 2003 Journal Tob Induc Dis Section Abstract Doc Link PMC2669561 Disease Relevance 0.78 Pain Relevance 0.39
At this concentration, lorglumide reduced mu, delta, kappa and CCK specific binding by 44%, 69%, 35% and 88%, whereas benzotript diminished it by 16%, 13%, 38% and 48%, respectively.
Negative_regulation (reduced) of CCK Binding (binding) of
4) Confidence 0.43 Published 1990 Journal Neuropeptides Section Abstract Doc Link 2174522 Disease Relevance 0.08 Pain Relevance 0.68
Reviews describe the regulation of CCK gene expression and CCK release, the nature of the hormone binding site of the CCK A receptor, interaction of CCK, dopamine and GABA, the role of CCK in thermoregulation, sexual behavior and satiety in rodents and humans.
Negative_regulation (describe) of CCK Binding (interaction) of associated with gaba and dopamine
5) Confidence 0.43 Published 2001 Journal Peptides Section Abstract Doc Link 11457511 Disease Relevance 0.15 Pain Relevance 0.25
Antagonism of the CCK1 receptor by JMV-179 blocked both CCK-8S and JMV-180 suppression of 3H-DAMGO binding.
Negative_regulation (blocked) of CCK-8S Binding (binding) of associated with cholecystokinin
6) Confidence 0.42 Published 2006 Journal Brain Res. Section Abstract Doc Link 16472782 Disease Relevance 0 Pain Relevance 1.32
In animals which showed almost total loss of GABAB receptors. 125I-Bolton Hunter CCK binding in the IPN was reduced from 1.83 +/- 0.28 pmol/g wet weight to 0.87 +/- 0.16 pmol/g wet weight.
Negative_regulation (reduced) of CCK Binding (binding) of in IPN associated with ipn
7) Confidence 0.42 Published 1988 Journal Brain Res. Section Abstract Doc Link 3408996 Disease Relevance 0 Pain Relevance 0.40
This article will review the experimental pharmacology of association of enkephalin-degrading enzyme inhibitors and CCK-B antagonists to demonstrate the interest of these molecules in the management of both pain and opioid addiction.
Negative_regulation (inhibitors) of CCK Binding (association) of associated with addiction, pain, antagonist, enkephalin, opioid and cholecystokinin
8) Confidence 0.39 Published 1996 Journal Neurochem. Res. Section Abstract Doc Link 8947930 Disease Relevance 0.42 Pain Relevance 1.62
We prepared various novel tricyclic 1,4-benzodiazepine derivatives as cholecystokinin (CCK) A antagonists, which were evaluated preliminarily for inhibition of 125I-CCK-8 binding to rat pancreatic membranes in vitro and inhibiting effect on CCK-8-induced inhibition of charcoal meal gastric emptying in mice.
Negative_regulation (inhibition) of 125I-CCK-8 Binding (binding) of associated with antagonist and cholecystokinin
9) Confidence 0.38 Published 1994 Journal Chem. Pharm. Bull. Section Abstract Doc Link 7805132 Disease Relevance 0 Pain Relevance 0.32
The hyperactivity induced by injection of the dopamine (DA) agonist apomorphine into the nucleus accumbens of rats was dose dependently inhibited by intra-accumbal pretreatment with cholecystokinin (CCK-8) (ED50, 0.34 ng).
Negative_regulation (inhibited) of cholecystokinin Binding (pretreatment) of in nucleus accumbens associated with nucleus accumbens, dopamine, agonist, attention deficit hyperactivity disorder and cholecystokinin
10) Confidence 0.37 Published 1987 Journal Neurosci. Lett. Section Abstract Doc Link 3561887 Disease Relevance 0.10 Pain Relevance 0.70
The hyperactivity induced by injection of the dopamine (DA) agonist apomorphine into the nucleus accumbens of rats was dose dependently inhibited by intra-accumbal pretreatment with cholecystokinin (CCK-8) (ED50, 0.34 ng).
Negative_regulation (inhibited) of CCK-8 Binding (pretreatment) of in nucleus accumbens associated with nucleus accumbens, dopamine, agonist, attention deficit hyperactivity disorder and cholecystokinin
11) Confidence 0.37 Published 1987 Journal Neurosci. Lett. Section Abstract Doc Link 3561887 Disease Relevance 0.10 Pain Relevance 0.71
In autoradiographic experiments, L-365,031 displaced 125I-Bolton Hunter CCK-8 binding from the interpeduncular nucleus (IPN) (IC50 = 7 X 10(-8) M), the area postrema (AP), and the nucleus tractus solitarius (NTS) without influencing specific binding to other areas, such as the cerebral cortex or the spinal tract of the trigeminal nerve.
Negative_regulation (displaced) of CCK Binding (binding) of in area postrema associated with fifth nerve, ipn and cerebral cortex
12) Confidence 0.35 Published 1987 Journal J. Neurosci. Section Abstract Doc Link 3625281 Disease Relevance 0 Pain Relevance 0.46
Tetronothiodin inhibited the binding of CCK8 (C-terminal octapeptide of CCK) to rat cerebral cortex membranes (CCK-B receptors), but did not inhibit CCK8 binding to rat pancreatic membranes (CCK-A receptors).
Negative_regulation (inhibit) of CCK8 Binding (binding) of in cerebral cortex associated with cerebral cortex and cholecystokinin
13) Confidence 0.30 Published 1999 Journal Crit Care Section Body Doc Link PMC137231 Disease Relevance 0.19 Pain Relevance 0.61
Tetronothiodin inhibited the binding of CCK8 (C-terminal octapeptide of CCK) to rat cerebral cortex membranes (CCK-B receptors), but did not inhibit CCK8 binding to rat pancreatic membranes (CCK-A receptors).
Negative_regulation (inhibited) of CCK8 Binding (binding) of in cerebral cortex associated with cerebral cortex and cholecystokinin
14) Confidence 0.26 Published 1999 Journal Crit Care Section Body Doc Link PMC137231 Disease Relevance 0.26 Pain Relevance 0.61
The potencies of agonists in stimulating and of antagonists in inhibiting CCK-8-stimulated SO contractions correlated closely with their abilities to inhibit binding of 125I-BH-CCK-8.
Negative_regulation (inhibit) of CCK Binding (binding) of associated with antagonist, agonist and cholecystokinin
15) Confidence 0.18 Published 1990 Journal Am. J. Physiol. Section Abstract Doc Link 2240227 Disease Relevance 0 Pain Relevance 1.13
Binding of 125I-BH-CCK-8 was inhibited by various CCK receptor agonists with the following potencies: CCK-8 much greater than des(SO3)CCK-8 much greater than gastrin-17-I and by various CCK receptor antagonists with the following potencies: L-364,718 greater than proglumide analogue 10 much greater than carbobenzoxy-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-NH2 greater than N2,O2' dibutyryl guanosine 3',5'-cyclic monophosphate.
Negative_regulation (inhibited) of CCK Binding (Binding) of associated with antagonist, agonist and cholecystokinin
16) Confidence 0.18 Published 1990 Journal Am. J. Physiol. Section Abstract Doc Link 2240227 Disease Relevance 0 Pain Relevance 0.75
Scatchard analysis indicated the inhibition of CCK binding by tifluadom was competitive in nature.
Negative_regulation (inhibition) of CCK Binding (binding) of
17) Confidence 0.17 Published 1986 Journal Neurosci. Lett. Section Abstract Doc Link 3027627 Disease Relevance 0 Pain Relevance 0.58
Tifluadom, a benzodiazepine kappa-opiate agonist, stereoselectively inhibited the binding of 125I-CCK to pancreatic membranes (IC50 = 47 nM).
Negative_regulation (inhibited) of CCK Binding (binding) of associated with agonist and opiate
18) Confidence 0.11 Published 1986 Journal Neurosci. Lett. Section Abstract Doc Link 3027627 Disease Relevance 0 Pain Relevance 0.57

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox